HC Wainwright Reaffirms Buy Rating for Akebia Therapeutics (NASDAQ:AKBA)

Posted by Stanley Muller on Jul 1st, 2026

Akebia Therapeutics (NASDAQ:AKBA – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $6.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 426.32% from the stock’s previous close.

A number of other equities research analysts have also recently commented on AKBA. BTIG Research reissued a “buy” rating and issued a $4.00 target price on shares of Akebia Therapeutics in a research note on Tuesday, April 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Akebia Therapeutics in a research note on Wednesday, May 6th. Zacks Research downgraded shares of Akebia Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen lowered shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Three equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, Akebia Therapeutics presently has a consensus rating of “Hold” and an average target price of $4.67.

Get Our Latest Stock Analysis on AKBA

Akebia Therapeutics Price Performance

Shares of AKBA opened at $1.14 on Wednesday. Akebia Therapeutics has a fifty-two week low of $0.82 and a fifty-two week high of $4.08. The firm’s 50-day simple moving average is $1.12 and its two-hundred day simple moving average is $1.32. The stock has a market cap of $305.82 million, a PE ratio of -14.25 and a beta of 0.26. The company has a debt-to-equity ratio of 1.33, a quick ratio of 1.33 and a current ratio of 1.40.

Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.02). Akebia Therapeutics had a negative return on equity of 62.72% and a negative net margin of 8.83%.The company had revenue of $53.54 million during the quarter, compared to the consensus estimate of $51.67 million. Analysts anticipate that Akebia Therapeutics will post -0.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Akebia Therapeutics

Several institutional investors have recently modified their holdings of the business. Baird Financial Group Inc. raised its position in Akebia Therapeutics by 23.0% in the 1st quarter. Baird Financial Group Inc. now owns 21,393 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 4,000 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Akebia Therapeutics by 26.0% during the 2nd quarter. Legal & General Group Plc now owns 23,279 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 4,798 shares during the last quarter. Polymer Capital Management US LLC grew its stake in shares of Akebia Therapeutics by 49.5% in the third quarter. Polymer Capital Management US LLC now owns 18,232 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 6,034 shares during the period. Deutsche Bank AG grew its stake in shares of Akebia Therapeutics by 5.2% in the fourth quarter. Deutsche Bank AG now owns 164,655 shares of the biopharmaceutical company’s stock worth $265,000 after acquiring an additional 8,103 shares during the period. Finally, Raymond James Financial Inc. raised its holdings in shares of Akebia Therapeutics by 16.8% during the second quarter. Raymond James Financial Inc. now owns 59,502 shares of the biopharmaceutical company’s stock valued at $217,000 after purchasing an additional 8,568 shares during the last quarter. 33.92% of the stock is owned by hedge funds and other institutional investors.

Akebia Therapeutics Company Profile

(Get Free Report)

Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.